Product Description
Mechanisms of Action: CCK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Trio Medicines
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Zollinger-Ellison Syndrome|Carcinoid Tumor|Gastrinoma|Gastritis, Atrophic|Barrett Esophagus|Healthy Volunteers|Gastritis
Phase 1: Esophagitis, Peptic|Peptic Ulcer|Dyspepsia|Pregnancy Outcomes|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| YF476 and type I gastric carcinoids | P2 |
Completed |
Gastritis, Atrophic |
2020-01-27 |
|
| Netazepide (YF476) in patients with Barrett's oesophagus; version 1 | P2 |
Completed |
Barrett Esophagus |
2019-10-10 |
|
| AAAE9648 | P2 |
Completed |
Barrett Esophagus |
2017-12-01 |
|
| T-016 | P2 |
Completed |
Barrett Esophagus |
2017-11-28 |